Arrowhead Pharmaceuticals Company Insiders
ARWR Stock | USD 14.51 0.99 6.39% |
Arrowhead Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Arrowhead Pharmaceuticals suggests that virtually all insiders are panicking. Arrowhead Pharmaceuticals employs about 609 people. The company is managed by 14 executives with a total tenure of roughly 33 years, averaging almost 2.0 years of service per executive, having 43.5 employees per reported executive.
Christopher Anzalone CEO CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-03-13 | Christopher Richard Anzalone | Disposed 51425 @ 15.07 | View | ||
2025-03-04 | Christopher Richard Anzalone | Disposed 133333 @ 17.02 | View | ||
2025-01-23 | Adeoye Y Olukotun | Disposed 959 @ 21 | View | ||
2025-01-06 | Patrick O'brien | Disposed 29184 @ 19.82 | View | ||
2025-01-02 | Christopher Richard Anzalone | Disposed 11520 @ 19.05 | View | ||
2024-12-27 | Adeoye Y Olukotun | Disposed 2850 @ 20 | View | ||
2024-12-23 | Christopher Richard Anzalone | Disposed 12563 @ 19.59 | View | ||
2024-12-18 | Christopher Richard Anzalone | Disposed 26712 @ 21.24 | View | ||
2024-12-16 | William D Waddill | Disposed 3748 @ 21.9 | View | ||
2024-07-02 | Tracie Oliver | Disposed 9394 @ 25.28 | View | ||
2024-05-02 | Victoria Vakiener | Disposed 1799 @ 23.31 | View |
Monitoring Arrowhead Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Arrowhead |
Arrowhead Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Arrowhead Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Arrowhead will maintain a workforce of slightly above 610 employees by April 2025.Arrowhead Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4771) % which means that it has lost $0.4771 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.6533) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/25/2025, Return On Tangible Assets is likely to drop to -0.5. In addition to that, Return On Capital Employed is likely to drop to -0.7. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 03/25/2025, Non Current Assets Total is likely to grow to about 536.5 M, while Net Tangible Assets are likely to drop slightly above 202.9 M.As of 03/25/2025, Common Stock Shares Outstanding is likely to grow to about 144.6 M, though Net Loss is likely to grow to (175.5 M).
Arrowhead Pharmaceuticals Workforce Comparison
Arrowhead Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 10,885. Arrowhead Pharmaceuticals holds roughly 609 in number of employees claiming about 6% of equities under Health Care industry.
Arrowhead Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arrowhead Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.4667 | 7 | 15 | 647,946 | 727,559 |
2024-12-01 | 0.7 | 7 | 10 | 200,398 | 64,161 |
2024-03-01 | 0.2308 | 9 | 39 | 445,499 | 283,716 |
2023-12-01 | 1.5 | 6 | 4 | 89,922 | 56,038 |
2023-09-01 | 0.5 | 2 | 4 | 115,310 | 68,230 |
2023-06-01 | 0.25 | 2 | 8 | 104,928 | 234,356 |
2023-03-01 | 0.7917 | 19 | 24 | 332,720 | 73,830 |
2022-12-01 | 0.75 | 3 | 4 | 284,400 | 82,125 |
2022-09-01 | 0.2 | 1 | 5 | 2,501 | 596,823 |
2022-03-01 | 0.325 | 13 | 40 | 1,177,994 | 424,757 |
2021-12-01 | 0.2 | 3 | 15 | 40,461 | 188,361 |
2021-03-01 | 0.3929 | 11 | 28 | 1,114,500 | 328,913 |
2020-12-01 | 0.25 | 10 | 40 | 213,847 | 561,904 |
2020-09-01 | 0.3333 | 1 | 3 | 50,000 | 100,000 |
2020-06-01 | 0.4615 | 18 | 39 | 98,653 | 414,581 |
2020-03-01 | 1.0 | 22 | 22 | 1,449,867 | 187,347 |
2019-12-01 | 0.1071 | 3 | 28 | 106,858 | 601,066 |
2019-09-01 | 0.3 | 3 | 10 | 112,650 | 408,545 |
2019-06-01 | 0.5 | 4 | 8 | 84,448 | 209,275 |
2019-03-01 | 0.6216 | 23 | 37 | 2,024,429 | 1,257,458 |
2018-12-01 | 0.3636 | 4 | 11 | 134,596 | 533,644 |
2018-09-01 | 0.3333 | 2 | 6 | 45,000 | 254,834 |
2018-06-01 | 0.5 | 4 | 8 | 54,000 | 131,600 |
2018-03-01 | 1.0 | 10 | 10 | 980,000 | 414,208 |
2016-09-01 | 0.6667 | 4 | 6 | 40,000 | 53,800 |
2016-06-01 | 2.0 | 2 | 1 | 24,289 | 15,772 |
2016-03-01 | 1.7143 | 12 | 7 | 1,205,000 | 115,218 |
2015-03-01 | 4.0 | 12 | 3 | 1,200,000 | 115,000 |
2014-12-01 | 1.25 | 5 | 4 | 154,500 | 52,500 |
2014-09-01 | 0.5556 | 5 | 9 | 62,000 | 124,000 |
2014-06-01 | 0.6667 | 2 | 3 | 22,000 | 44,000 |
2014-03-01 | 1.6 | 16 | 10 | 786,000 | 175,148 |
2013-12-01 | 3.0 | 3 | 1 | 3,500 | 28,000 |
2013-09-01 | 3.5 | 7 | 2 | 157,991 | 40,000 |
2013-06-01 | 6.0 | 6 | 1 | 475,000 | 105,000 |
2013-03-01 | 0.6667 | 4 | 6 | 65,000 | 110,000 |
2012-09-01 | 0.6 | 3 | 5 | 100,000 | 75,000 |
2012-03-01 | 0.4286 | 3 | 7 | 363,000 | 227,000 |
2010-09-01 | 2.5 | 5 | 2 | 655,000 | 200,000 |
2010-03-01 | 5.0 | 5 | 1 | 1,003,250 | 10,000 |
2008-09-01 | 2.0 | 2 | 1 | 328,000 | 54,688 |
2008-06-01 | 2.0 | 4 | 2 | 175,000 | 2,100,000 |
2007-03-01 | 0.2727 | 6 | 22 | 437,000 | 1,451,572 |
2005-12-01 | 0.5 | 1 | 2 | 750,000 | 25,000 |
2005-06-01 | 1.75 | 14 | 8 | 2,925,063 | 1,459,242 |
2005-03-01 | 0.3333 | 1 | 3 | 25,000 | 60,000 |
2004-12-01 | 0.8 | 4 | 5 | 40,000 | 136,000 |
2004-03-01 | 0.2727 | 3 | 11 | 350,000 | 1,344,487 |
Arrowhead Pharmaceuticals Notable Stakeholders
An Arrowhead Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arrowhead Pharmaceuticals often face trade-offs trying to please all of them. Arrowhead Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arrowhead Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher Anzalone | CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics | Profile | |
Nadia MBA | VP Treasurer | Profile | |
CPA CPA | Chief Officer | Profile | |
Kenneth Myszkowski | Chief Officer | Profile | |
Javier MD | Chief Officer | Profile | |
Bruce MD | Chief Scientist | Profile | |
Vincent CFA | Head VP | Profile | |
MBA MD | Chief Medicine | Profile | |
Tracie Oliver | Chief Officer | Profile | |
Aaron Tan | Head Tax | Profile | |
PharmD JD | COO Counsel | Profile | |
Howard Lovy | Director Communications | Profile | |
Mark Davis | Founder Calando | Profile | |
Mark Seefeld | Head VP | Profile |
About Arrowhead Pharmaceuticals Management Performance
The success or failure of an entity such as Arrowhead Pharmaceuticals often depends on how effective the management is. Arrowhead Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arrowhead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arrowhead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.48) | (0.50) | |
Return On Capital Employed | (0.67) | (0.70) | |
Return On Assets | (0.47) | (0.50) | |
Return On Equity | (3.72) | (3.53) |
Arrowhead Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Arrowhead Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arrowhead Pharmaceuticals within its industry.Arrowhead Pharmaceuticals Manpower Efficiency
Return on Arrowhead Pharmaceuticals Manpower
Revenue Per Employee | 5.8K | |
Revenue Per Executive | 253.6K | |
Net Loss Per Employee | 1M | |
Net Loss Per Executive | 43.5M | |
Working Capital Per Employee | 972.6K | |
Working Capital Per Executive | 42.3M |
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.